Development of a Fatigue and Functional Impact Scale in anemic cancer patients receiving chemotherapy

Cancer

Volumn 113, Issue 6, 2008, Pages 1480-1488

  Cella, David ^a,g   Viswanathan, Hema N ^b   Hays, Ron D ^c   Mendoza, Tito R ^d   Stein, Kevin D ^e   Pasta, David J ^f   Foreman, Aimee J ^f   Vadhan Raj, Saroj ^d   Kallich, Joel D ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e BEHAVIORAL RESEARCH CENTER   (United States)

^f ICON CLINICAL RESEARCH   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anemia; Fatigue; Health related quality of life; Measurement; Oncology

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; BRIEF FATIGUE INVENTORY; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FATIGUE AND FUNCTIONAL IMPACT SCALE; FATIGUE SYMPTOM INVENTORY; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPHY FATIGUE; GYNECOLOGIC CANCER; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OXYGEN CONSUMPTION; PERFORMANCE; PRIORITY JOURNAL; PRODUCTIVITY; RATING SCALE; SELF REPORT; SHORT FORM 36; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CLINICAL TRIALS, PHASE II AS TOPIC; ERYTHROPOIETIN; FATIGUE; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE;

EID: 53149122065     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23698     Document Type: Article

References (34)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91:1616-1634.
2. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. j Clin Oncol. 1997;15:1218-1234.
3. Littlewood TJ, Bajetta E, Nortier J, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
4. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-oflife benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-3425.
5. Gabrilove JL, Cleeland C, Livingston RB, Sarokhan B, Winer E, Einhorn L. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to 3-timesweekly dosing. J Clin Oncol. 2001;19:2875-2882.
6. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol. 1998;25:43-46.
7. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology (Huntingt). 1998;12:369-377.
8. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology. 2005;69 (suppl 2):2-7.
9. Mallinson T, Cella D, Cashy J, Holzner B. Giving meaning to measure: linking self-reported fatigue and function to performance of everyday activities. J Pain Symptom Manage. 2006;31:229-241.
10. Hwang SS, Chang VT, Cogswell J, Kasimis BS. Clinical relevance of fatigue levels in cancer patients at a Veterans Administration Medical Center. Cancer. 2002;94:2481-2489.
11. Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res. 1998;7:301-310.
12. Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology (Huntingt). 2002;16:17-24.
13. Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer. 2004;91:822-828.
14. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol. 1997;34:4-12.
15. Curt G, Johnston PG. Cancer fatigue: the way forward. Oncologist. 2003;8(suppl 1):27-30.
16. Dillon E, Kelly J. The status of cancer fatigue on the Island of Ireland: AIFC professional and interim patient surveys. Oncologist. 2003;8(suppl 1):22-26.
17. Van Belle S, Paridaens R, Evers G, et al. Comparison of pro posed diagnostic criteria with FACT-F and VAS for cancerrelated fatigue: proposal for use as a screening tool. Support Care Cancer. 2005;13:246-254.
18. Kirsh KL. Passik S, Holtsclaw K, Donaghy K, Theobald D. I get tired for no reason: a single item screening for cancer-related fatigue. J Pain Symptom Manage. 2001;22:931-937.
19. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13: 63-74.
20. Piper B, Lindsey A, Dodd M. The development of an instrument to measure the subjective dimension of fatigue. In: Funk SG, Tornquist EM, Champagne MT, et al, eds. Key Aspects of Comfort: Management of Pain, Fatigue and Nausea. New York: Springer Publishing; 1989:199-208.
21. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315-325.
22. Francis KT. Fitness assessment using step tests. Compr Ther. 1987;13:36-41.
23. Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every 2 weeks. J Support Oncol. 2003;1:131-138.
24. Astrand PO, Ryhming I. A nomogram for calculation of aerobic capacity (physical fitness) from pulse rate during submaximal work. J Appl Physiol. 1954;7:218-221.
25. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186-1196.
26. Reise SP, Morizot J, Hays RD. The role of the bifactor model in resolving dimensionality issues in health outcomes measures. Qual Life Res. 2007;16(suppl 1):19-31.
27. Borg G. Borg's Perceived Exertion and Pain Scales. Champaign, IL: Human Kinetics; 1998.
28. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
29. Schwartz AL. The Schwartz Cancer Fatigue Scale: testing reliability and validity. Oncol Nurs Forum. 1998;25:711-717.
30. Lai JS, Cella D, Chang CH, Bode RK, Heinemann AW. Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res. 2003;12:485-501.
31. Lai JS, Crane PK, Cella D. Factor analysis techniques for assessing sufficient unidimensionality of cancer related fatigue. Qual Life Res. 2006;15:1179-1190.
32. Haughey MT, Calderon Y, Torres S, Nazario S, Bijur P. Identification of depression in an inner-city population using a simple screen. Acad Emerg Med. 2005;12:1221-1226.
33. Carroll JC, Reid AJ, Biringer A, et al. Effectiveness of the Antenatal Psychosocial Health Assessment (ALPHA) form in detecting psychosocial concerns: a randomized controlled trial. CMAJ. 2005;173:253-259.
34. Garcia SF, Cella D, Clauser SB, et al. Standardizing patientreported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol. 2007;25:5106-5112.